Evidence map›Paper›PMID 27935861›Full record

ArticleOncotarget2017

MicroRNA-203 predicts human survival after resection of colorectal liver metastasis.

T Peter Kingham, Hoang C B Nguyen, Jian Zheng, Ioannis T Konstantinidis, Eran Sadot, Jinru Shia, Deborah Kuk, Steven Zhang, Leonard Saltz, Michael I D'Angelica and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Thermal Ablation of Metastatic Colon Cancer to the Liver.Seminars in interventional radiology · 2019
    Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

T Peter KinghamDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hoang C B NguyenLaboratory of Systems Cancer Biology, The Rockefeller University, New York, NY, USA.
Jian ZhengDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ioannis T KonstantinidisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eran SadotDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jinru ShiaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Deborah KukDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Steven ZhangLaboratory of Systems Cancer Biology, The Rockefeller University, New York, NY, USA.
Leonard SaltzDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael I D'AngelicaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
William R JarnaginDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hani GoodarziDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Sohail F TavazoieLaboratory of Systems Cancer Biology, The Rockefeller University, New York, NY, USA.
Memorial Sloan Kettering Cancer Center · USRockefeller University · USUniversity of California, San Francisco · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Systematic dissection of an aberrant splicing program driving cancer metastasisR00CA194077 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOODARZI, HANI · 2016 to 2018
$746k
NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA194077
6 · The paper itself

Abstract

backgroundResection of colorectal liver metastasis (CRLM) can be curative. Predicting which patients may benefit from resection, however, remains challenging. Some microRNAs (miRNAs) become deregulated in cancers and contribute to cancer progression. We hypothesized that miRNA expression can serve as a prognostic marker of survival after CRLM resection.

resultsMiR-203 was significantly overexpressed in tumors of short-term survivors compared to long-term survivors. R1/R2 margin status and high clinical risk score (CRS) were also significantly associated with short-term survival (both p = 0.001). After adjusting for these variables, higher miR-203 expression remained an independent predictor of shorter survival (p = 0.010). In the serum cohort, high CRS and KRAS mutation were significantly associated with short-term survival (p = 0.005 and p = 0.026, respectively). After adjusting for CRS and KRAS status, short-term survivors were found to have significantly higher miR-203 levels (p = 0.016 and p = 0.033, respectively). MATERIALS AND

methodsWe employed next-generation sequencing of small-RNAs to profile miRNAs in solid tumors obtained from 38 patients who underwent hepatectomy for CRLM. To validate, quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was performed on 91 tumor samples and 46 preoperative serum samples.

conclusionsAfter CRLM resection, short-term survivors exhibited significantly higher miR-203 levels relative to long-term survivors. MiR-203 may serve as a prognostic biomarker and its prognostic capacity warrants further investigation.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCohort StudiesColorectal NeoplasmsFemaleHigh-Throughput Nucleotide SequencingHumansLiver NeoplasmsMaleMicroRNAsMiddle AgedReverse Transcriptase Polymerase Chain ReactionSurvival AnalysisBiomarkers, TumorMicroRNAsMIRN203 microRNA, humancolorectal liver metastasismicroRNAmiR-203resectionsurvival

Identifiers

PMID27935861
PMCPMC5386650
OpenAlexW2560672969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.